ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Head and Neck Cancer
Interventions
COMBINATION_PRODUCT

ASP-1929 Photoimmunotherapy

Use of ASP-1929 PIT therapy

DRUG

Physician's Choice SOC

docetaxel, cetuximab, methotrexate, paclitaxel

Trial Locations (22)

10048

Cancer Clinic, Taipei

19107

Cancer Clinic 1, Philadelphia

Cancer Clinic 2, Philadelphia

30322

Cancer Clinic, Atlanta

33176

Cancer Clinic, Miami

33305

Cancer Clinic, Taoyuan District

33606

Cancer Clinic, Tampa

40536

Cancer Clinic, Lexington

40705

Cancer Clinic, Taichung

77030

Cancer Clinic, Houston

390011

Cancer Clinic, Vadodara

391760

Cancer Clinic, Vadodara

400012

Cancer Clinic, Mumbai

500034

Cancer Clinic, Hyderabad

560099

Cancer Clinic, Bangalore

600036

Cancer Clinic, Chennai

682041

Cancer Clinic, Kochi

700160

Cancer Clinic, Kolkata

464-8681

Cancer Clinic, Nagoya

060-8648

Cancer Clinic, Sapporo

700-8558

Cancer Clinic, Okayama

104-0045

Cancer Clinic, Chuo-ku

All Listed Sponsors
lead

Rakuten Medical, Inc.

INDUSTRY

NCT03769506 - ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | Biotech Hunter | Biotech Hunter